Abstract
Eight children treated between 1977 and 1983 with the UK Children's Cancer Study Group's non-Hodgkin lymphoma (NHL) and T-cell protocols have developed second malignancies within 7 years of commencing treatment. Five developed acute non-lymphoblastic leukaemia and a sixth died from infection while pancytopenic with a pre-leukaemic marrow. The other malignancies were cerebral astrocytoma and an undifferentiated low grade sarcoma. These eight children were included among 261 children studied in the first UKCCSG NHL and T-cell trials giving an actuarial incidence of 7.8% second malignancy at 7 years. Six had received adjuvant radiotherapy which may have contributed to the high incidence of second malignancy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Ingram, L., Mott, M., Mann, J. et al. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer 55, 463–466 (1987). https://doi.org/10.1038/bjc.1987.91
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.91
This article is cited by
-
Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study
Leukemia (2019)
-
Therapy Related AML/MDS Following Treatment for Childhood Cancer: Experience from a Tertiary Care Centre in North India
Indian Journal of Hematology and Blood Transfusion (2018)
-
What’s All the Fuss About? Facts and Figures About Bone Marrow Failure and Conditions
Current Hematologic Malignancy Reports (2012)